We caught up with Mark Yates (King’s College London, London, UK) to discuss risk mitigating behaviours during the COVID-19 pandemic in patients with immune-mediated inflammatory diseases who use biologics. The abstract ‘Risk Mitigating Behaviour in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study’ (ABSTRACT NUMBER: L02) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What is known about the risks of adverse COVID-19 outcomes in people with immune-mediated inflammatory diseases (IMIDs) who use biologics? (0:29)
- How might risk-mitigating behaviours confound these findings? (1:49)
- Could you tell us a little about your study in people with rheumatic diseases or psoriasis? (2:31)
- What were the findings of the study? (3:40)
- How can these data be used to improve communications between clinicians and vulnerable patients? (4:32)
Disclosures: Dr Yates reports receiving honoraria from Abbvie.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR Convergence 2020 (Virtual).
Share this Video
Related Videos In Rheumatoid Arthritis
Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 1)
We were delighted to speak to Anthony Sebba (Arthritis Associates, FL, USA) to discuss whether pain and inflammation are independent of each other in patients with rheumatoid arthritis. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in […]
Peter C Taylor, ACR 2020 – Therapy Reduction in RA Patients in Remission: The SEAM-RA Trial (Part 1)
Following ACR Convergence 2020 we speak with Peter C Taylor (University of Oxford, Oxford, UK) about his highlights from the meeting. Part 1 in the series covers the SEAM-RA study designed to investigate the effect of therapy reduction in RA patients with persistent submission receiving a combination of methotrexate and etanercept. The abstract entitled ‘Maintenance […]
Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 3)
After his presentation at ACR 2020, we spoke with Anthony Sebba (Arthritis Associates, FL, USA) about the importance of studying pain as a patient reported outcome in rheumatoid arthritis and what further studies are needed. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!